Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.32, $0.09 better than the analyst estimate of $1.23. Revenue for the quarter came in at $5.06 billion versus the consensus estimate of $5.09 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.